Jichishiyao Pharmaceutical Group-B (02616.HK) released its interim results, with research and development expenditures reaching 105 million yuan, an increase of 58.75% year-on-year.

Wisdom Finance and Economics APP News, Cornerstone Pharmaceutical-B (02616.HK) announced its interim performance for the six months ended June 30, 2025. The group achieved revenue of RMB 49.45 million (same unit), a decrease of 80.54% year-on-year; research and development expenses were RMB 105 million, an increase of 58.75% year-on-year; the company incurred a loss of RMB 270 million during the period, with a basic loss per share of 0.21 yuan.